Abstract

Toxoplasma gondii encephalitis occurs in up to 30% of HIV-infected individuals with latent infection. Anti-toxoplasma chemotherapy is often toxic, and despite adequate therapy, disease recurs in up to 50% of patients with AIDS. An understanding of the cellular immune response to T. gondii infection may aid in the development of improved predictors of the risk for recrudescent disease, and may lead to effective immunotherapies. We have constructed recombinant vaccinia viruses that express the 28-kD toxoplasma antigen. A second vector that expresses the p22 antigen of T. gondii is currently being constructed in our laboratory. By using these vectors to induce autologous EBV-transformed lymphoblasts to express toxoplasma antigens, we can examine cytotoxic T-cell activity of cells derived from individuals with a history of T. gondii infection. We propose to study toxoplasma-specific CTL responses of T. gondii-seropositive, HIV- infected individuals.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032770-08
Application #
6099562
Study Section
Project Start
1999-01-01
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Fischl, Margaret A; Collier, Ann C; Mukherjee, A Lisa et al. (2007) Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 21:325-33
Wilkin, Timothy J; Su, Zhaohui; Kuritzkes, Daniel R et al. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44:591-5
Okusanya, Olanrewaju; Forrest, Alan; DiFrancesco, Robin et al. (2007) Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother 51:1822-6
Mulligan, Kathleen; Zackin, Robert; Von Roenn, Jamie H et al. (2007) Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 92:563-70

Showing the most recent 10 out of 55 publications